Drug Resistance

"Drug Resistance" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration.

Descriptor ID	D004351
MeSH Number(s)	G07.690.773.984
Concept/Terms	Drug Resistance Drug Resistance Resistance, Drug

Below are MeSH descriptors whose meaning is more general than "Drug Resistance".

Biological Sciences [G]
Physiological Phenomena [G07]
Pharmacological and Toxicological Phenomena [G07.690]
Pharmacological Phenomena [G07.690.773]
Drug Resistance [G07.690.773.984]

Below are MeSH descriptors whose meaning is related to "Drug Resistance".

Below are MeSH descriptors whose meaning is more specific than "Drug Resistance".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Drug Resistance" by people in this website by year, and whether "Drug Resistance" was a major or minor topic of these publications.

Bar chart showing 116 publications over 26 distinct years, with a maximum of 12 publications in 2024

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	0	2	2
1996	0	3	3
2001	0	1	1
2003	0	2	2
2004	0	2	2
2005	6	1	7
2006	0	4	4
2007	0	4	4
2008	0	2	2
2009	0	2	2
2010	1	2	3
2011	4	6	10
2012	0	2	2
2013	2	2	4
2014	2	1	3
2015	2	1	3
2016	2	3	5
2017	6	2	8
2018	2	2	4
2019	3	0	3
2020	2	4	6
2021	2	3	5
2022	0	8	8
2023	1	4	5
2024	9	3	12
2025	5	1	6

Below are the most recent publications written about "Drug Resistance" by people in Profiles.

Martin AC, Sadler JM, Simkin A, Musonda M, Katowa B, Matoba J, Schue J, Simulundu E, Bailey JA, Moss WJ, Juliano JJ, Fola AA. Emergence and Rising Prevalence of Artemisinin Partial Resistance Marker Kelch13 P441L in a Low Malaria Transmission Setting in Southern Zambia. J Infect Dis. 2025 Oct 15; 232(4):918-922.

View in: PubMed
Okitwi M, Orena S, Tumwebaze PK, Katairo T, Taremwa Y, Byaruhanga O, Tukwasibwe S, Nsobya SL, Legac J, Bailey JA, Cooper RA, Conrad MD, Rosenthal PJ. Changes in susceptibility of Plasmodium falciparum to antimalarial drugs in Uganda over time: 2019-2024. Nat Commun. 2025 Aug 09; 16(1):7353.

View in: PubMed
Rosado J, Fola AA, Cojean S, Sarrasin V, Copp?e R, Bailly J, Zaffaroulah R, Bouzayene A, Cic?ron L, Houz? L, Crudale R, Musset L, Thellier M, Pradines B, Clain J, Bailey JA, Houz? S. Assessment of ex vivo antimalarial drug efficacy in African Plasmodium falciparum parasite isolates, 2016-2023: a genotype-phenotype association study. EBioMedicine. 2025 Aug; 118:105835.

View in: PubMed
Katairo T, Asua V, Nsengimaana B, Tukwasibwe S, Semakuba FD, Wiringilimaana I, Kagurusi BA, Mwubaha C, Nakasaanya J, Garg S, Kiyaga S, Mbabazi M, Kabbale KD, Ayitewala A, Nsobya SL, Kamya MR, Ssewanyana I, Bailey JA, Aranda-D?az A, Rosenthal PJ, Greenhouse B, Briggs J, Conrad MD. Performance of molecular inversion probe DR23K and Paragon MAD4HatTeR Amplicon sequencing panels for detection of Plasmodium falciparum mutations associated with antimalarial drug resistance. Malar J. 2025 Jun 12; 24(1):188.

View in: PubMed
Meier-Scherling CPG, Watson OJ, Asua V, Ghinai I, Katairo T, Garg S, Conrad MD, Rosenthal PJ, Okell LC, Bailey JA. Selection of Plasmodium falciparum kelch13 mutations in Uganda in comparison with southeast Asia: a modelling study. Lancet Microbe. 2025 May; 6(5):101027.

View in: PubMed
Wernsman Young N, Gashema P, Giesbrecht D, Munyaneza T, Maisha F, Mwebembezi F, Budodo R, Leonetti A, Crudale R, Iradukunda V, Jean Bosco N, Kirby RI, Boyce RM, Mandara CI, Kanyankole GK, Ntaro M, Okell LC, Watson OJ, Mulogo E, Ishengoma DS, Hangi S, Karema C, Mazarati JB, Juliano JJ, Bailey JA. High Frequency of Artemisinin Partial Resistance Mutations in the Great Lakes Region Revealed Through Rapid Pooled Deep Sequencing. J Infect Dis. 2025 Feb 04; 231(1):269-280.

View in: PubMed
Popkin-Hall ZR, Niar? K, Crudale R, Simkin A, Fola AA, Sanchez JF, Pannebaker DL, Giesbrecht DJ, Kim IE, Aydemir ?, Bailey JA, Valdivia HO, Juliano JJ. High-throughput genotyping of Plasmodium vivax in the Peruvian Amazon via molecular inversion probes. Nat Commun. 2024 11 25; 15(1):10219.

View in: PubMed
Okitwi M, Shoue DA, Checkley LA, Orena S, Ceja FG, Taremwa Y, Tumwebaze PK, Katairo T, Byaruhanga O, Sievert MA, Garg S, Kreutzfeld OK, Legac J, Bailey JA, Nsobya SL, Conrad MD, Rosenthal PJ, Ferdig MT, Cooper RA. The extended recovery ring-stage survival assay is a scalable alternative for artemisinin susceptibility phenotyping of fresh Plasmodium falciparum isolates. Antimicrob Agents Chemother. 2024 12 05; 68(12):e0118324.

View in: PubMed
Fola AA, Kobayashi T, Hamapumbu H, Musonda M, Katowa B, Matoba J, Stevenson JC, Norris DE, Thuma PE, Wesolowski A, Moss WJ, Juliano JJ, Bailey JA. Temporal genomics in Southern Zambia shows rising prevalence of Plasmodium falciparum mutations linked to delayed clearance after artemisinin-lumefantrine treatment. Sci Rep. 2024 11 05; 14(1):26789.

View in: PubMed
Ishengoma DS, Mandara CI, Bakari C, Fola AA, Madebe RA, Seth MD, Francis F, Buguzi CC, Moshi R, Garimo I, Lazaro S, Lusasi A, Aaron S, Chacky F, Mohamed A, Njau RJA, Kitau J, Rasmussen C, Bailey JA, Juliano JJ, Warsame M. Evidence of artemisinin partial resistance in northwestern Tanzania: clinical and molecular markers of resistance. Lancet Infect Dis. 2024 Nov; 24(11):1225-1233.

View in: PubMed

People

Explore

Similar Concepts

Top Journals